Chronic pain gene identified

September 8, 2011 By Sunanda Creagh, The Conversation

British researchers say they have identified the gene that controls chronic pain, opening the door to new drug therapies that block the chemical processes that cause chronic back pain, headaches or arthritis.

Chronic pain, defined as pain that is experienced most days of the week for at least three months, afflicts around 1 in 5 Australians. It commonly disrupts a sufferer’s ability to lead a normal life.

Now a team led by Professor Peter McNaughton, Head of the Department of Pharmacology at the University of Cambridge, has isolated a gene called HCN2 that produces a protein that causes chronic pain.

“Individuals suffering from neuropathic pain often have little or no respite because of the lack of effective medications. Our research lays the groundwork for the development of new drugs to treat chronic pain by blocking HCN2,” said Professor McNaughton.

His team conducted a series of experiments on mice genetically engineered to be born without the HCN2 gene. The researchers observed that these mice responded normally to normal acute pain (which is produced by a sudden injury) but that removing the HCN2 gene abolished neuropathic pain.

Being able to control chronic pain without affecting normal pain responses was crucial, he said.

“Many genes play a critical role in pain sensation, but in most cases interfering with them simply abolishes all pain, or even all sensation,” Professor McNaughton said.

“This finding could be very valuable clinically because normal pain sensation is essential for avoiding accidental damage.”

Professor Richard Lewis, an expert on from the University of Queensland’s Institute for Molecular Bioscience, said the breakthrough was significant.

“This work appears particularly exciting as it, for the first time, directly links pacemaker channel HCN2 — a membrane protein important in controlling cell excitability — to the development of several difficult-to-treat painful conditions but not normal pain sensations,” said Professor Lewis, who was not involved in the research.

Chemical disruption of HCN2 could form the basis of much needed new pain therapies, he said.

“Building on previous research in this area, the work now highlights opportunities to discover and develop safer and more effective pain therapies that can selectively target HCN2 in pathways.”

The UK study was published in the September 9 edition of the journal Science.


This story is published courtesy of the The Conversation (under Creative Commons-Attribution/No derivatives).

Related Stories

Recommended for you

Scientists identify new way cells turn off genes

July 19, 2017
Cells have more than one trick up their sleeve for controlling certain genes that regulate fetal growth and development.

South Asian genomes could be boon for disease research, scientists say

July 18, 2017
The Indian subcontinent's massive population is nearing 1.5 billion according to recent accounts. But that population is far from monolithic; it's made up of nearly 5,000 well-defined sub-groups, making the region one of ...

Mutant yeast reveals details of the aberrant genomic machinery of children's high-grade gliomas

July 18, 2017
St. Jude Children's Research Hospital biologists have used engineered yeast cells to discover how a mutation that is frequently found in pediatric brain tumor high-grade glioma triggers a cascade of genomic malfunctions.

Late-breaking mutations may play an important role in autism

July 17, 2017
A study of nearly 6,000 families, combining three genetic sequencing technologies, finds that mutations that occur after conception play an important role in autism. A team led by investigators at Boston Children's Hospital ...

Newly discovered gene variants link innate immunity and Alzheimer's disease

July 17, 2017
Three new gene variants, found in a genome wide association study of Alzheimer's disease (AD), point to the brain's immune cells in the onset of the disorder. These genes encode three proteins that are found in microglia, ...

Newly identified genetic marker may help detect high-risk flu patients

July 17, 2017
Researchers have discovered an inherited genetic variation that may help identify patients at elevated risk for severe, potentially fatal influenza infections. The scientists have also linked the gene variant to a mechanism ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.